Ladenburg Thalmann maintains NovoCure at Buy, raises price target to $31 from $27

Ladenburg Thalmann raised its price target for NovoCure to $31 from $27, maintaining a Buy rating. The new target suggests a 162.5% upside from the Nov 10 close of $11.81. Other recent analyst targets for NovoCure range from $15 to $20.

Original reporting
Published Nov 10, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ladenburg Thalmann maintains NovoCure at Buy, raises price target to $31 from $27 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The upgrade may cause a short-lived rally but lacks a substantive catalyst.

02

Market read

Limited to investors tracking analyst opinions on biotech stocks.

03

What to watch

No new product or trial results were disclosed, so the upgrade rests on limited information.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst price target adjustments are routine and often reflect internal research rather than fresh market events.

Market effects

May slightly boost sentiment in the biotech/oncology sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

The target raise could be premature without new clinical data; price may revert.

Key entities

  • NovoCure

    Biotech firm developing oncolytic immunotherapy.

  • Ladenburg Thalmann

    Equity research firm issuing the price target.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.